Mawson Lakes Office, IW 2-1908 83023569
Professor of Pharmaceutical Science
Clive Prestidge is currently a Professor within Clinical and Health Science, a lead researcher within UniSA's Cancer Research Institute and head of the Nanostructure and Drug Delivery research group.
Clive is the author of over 250 refereed international journal articles, textbook chapters and conference papers and over 100 major project reports to industry. He has supervised more than 35 PhD, 10 MSc and 30 Honours students and has taken a leadership role in a number of major collaborative projects in association with national and international industries, the ARC, and University researchers from Australia and overseas. Prof Prestidge has attracted competitive research grants worth more than... Read more
About me
Professor of Pharmaceutical Science
Clive Prestidge is currently a Professor within Clinical and Health Science, a lead researcher within UniSA's Cancer Research Institute and head of the Nanostructure and Drug Delivery research group.
Clive is the author of over 250 refereed international journal articles, textbook chapters and conference papers and over 100 major project reports to industry. He has supervised more than 35 PhD, 10 MSc and 30 Honours students and has taken a leadership role in a number of major collaborative projects in association with national and international industries, the ARC, and University researchers from Australia and overseas. Prof Prestidge has attracted competitive research grants worth more than $15M from government and industry sources.
Clive was the founder of Ceridia Pty Ltd, a clinical stage biopharmaceutical company established to commercial the the Lipoceramic drug delivery technology he invented.
The Prestidge research group is focused on Drug delivery, Nanomedicine and BioPharmaceutical Engineering. Its Primary Mission is to: (1) Engineer novel particle based biomaterials with specific biological activity and their application to solve biopharmaceutical challenges. (2) Determine mechanisms for bioactivity through advanced biophysical analysis (3) Develop drug delivery solutions to address unmet clinical needs. Some of our Grand Challenges are to: (1) Deliver Challenging Therapeutic Molecules – For Better Medicines (2) Eradicate Bacterial Biofilms (3) Optimise Biotech and Pharmaceutical Processing and Manufacture
About me
About me
Doctor of Philosophy University of Bristol
Bachelor of Science University of Loughborough
The Prestidge research group is focused on Nanomedicine and BioPharmaceutical Engineering. Its Primary Mission is to: (1) Engineer novel particle based biomaterials with specific biological activity and their application to solve biopharmaceutical challenges. (2) Determine mechanisms for bioactivity through advanced biophysical analysis (3) Develop drug delivery solutions to address unmet clinical needs. Some of our Grand Challenges are to: (1) Deliver Challenging Therapeutic Molecules – For Better Medicines (2) Eradicate Bacterial Biofilms (3) Optimise Biotech and Pharmaceutical Processing and Manufacture
Research
Excludes commercial-in-confidence projects.
Maximising the antimicrobial and anti-inflammatory performance of next generation therapeutics for Chronic Rhinosinusitis, NHMRC - Project Grant, 01/01/2019 - 31/12/2021
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, ARC - Centre of Excellence, 01/04/2014 - 29/06/2021
Optimization and validation of assay of French protocol for phenotyping patient samples for treatment optimization, Pari-Passou Medical Consultancy, 03/08/2020 - 31/12/2020
Mechanistic insight into Pharmako's Oral Curcumin Product: LipiSperse®, Pharmako Biotechnologies Pty Ltd, 03/10/2018 - 25/12/2019
Targeting particulate carriers to epithelial M cells, ARC - Linkage Project, 15/12/2015 - 30/09/2019
Targeting Particulate Carriers to Epithelial M Cells, CeramiSphere Pty Ltd, 01/01/2016 - 30/06/2019
Lipoceramic reformulation of simvastatin, Reformpharm Pty Ltd, 23/11/2016 - 31/12/2017
Research Infrastructure Fund (RIF) Grant 2016 Round 2 - Biofilm Testing Facility, Adelaide Integrated Bioscience Laboratories, 28/11/2016 - 31/12/2017
Mobilisation of endogenous mesenchymal progenitor cells for growth plate regeneration, NHMRC - Project Grant, 01/01/2013 - 31/12/2016
Improving the taste, bioavailability and efficacy of orally administered praziquantel for yellowtail kingfish with lipid nanoparticles and hybrid lipid carrier systems, Challenger Institute of Technology, 23/06/2015 - 30/09/2016
A novel nitric oxide-based treatment for recalcitrant Staphylococcus aureus-associated chronic rhinosinusitis (admin by Uni of Adelaide), NHMRC - Project Grant, 01/01/2013 - 30/06/2016
Harnessing lipid nano-assembly for next generation functional foods and pharmaceutical products, ARC - Discovery Projects, 01/01/2012 - 31/12/2015
A nanostructured drug delivery approach for improved colorectal cancer therapy, NHMRC - Project Grant, 01/01/2012 - 31/12/2015
Smart hybrid nano-biomaterials that mimic pharmaceutical food effect, ARC - Discovery Projects, 16/03/2012 - 30/09/2015
Research
Research outputs for the last seven years are shown below. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2016 |
33
31
4
|
2015 |
Open access
182
174
263
|
2015 |
26
25
|
Year | Output |
---|---|
2020 |
3
1
|
2016 |
|
2014 |
6
|
2014 |
1
|
2012 |
1
1
|
2008 |
|
Year | Output |
---|---|
2023 |
Open access
|
2023 |
Open access
|
2023 |
Open access
|
2023 |
Open access
2
2
1
|
2022 |
2
2
3
|
2022 |
3
3
6
|
2022 |
Open access
2
1
|
2022 |
9
8
12
|
2022 |
Open access
3
1
3
|
2022 |
Open access
|
2022 |
5
3
5
|
2022 |
Open access
|
2022 |
7
7
54
|
2022 |
2
3
3
|
2022 |
3
3
8
|
2022 |
Open access
|
2022 |
3
1
|
2022 |
1
1
2
|
2022 |
Open access
1
1
335
|
2022 |
Open access
|
2022 |
1
|
2021 |
5
4
50
|
2021 |
Open access
10
7
1
|
2021 |
10
11
7
|
2021 |
Open access
11
11
|
2021 |
Open access
4
3
|
2021 |
Open access
11
9
4
|
2021 |
Open access
3
3
4
|
2021 |
Open access
2
2
5
|
2021 |
24
21
11
|
2021 |
Open access
20
17
|
2021 |
20
19
68
|
2021 |
14
12
8
|
2021 |
8
6
63
|
2021 |
Open access
21
17
4
|
2021 |
5
5
|
2021 |
Open access
6
6
10
|
2020 |
18
16
32
|
2020 |
Open access
5
5
2
|
2020 |
Open access
5
4
1
|
2020 |
Open access
9
9
21
|
2020 |
Open access
2
2
|
2020 |
Open access
10
10
2
|
2020 |
Open access
11
12
2
|
2020 |
3
3
|
2020 |
14
13
4
|
2020 |
7
6
1
|
2020 |
Open access
19
19
|
2020 |
8
8
|
2020 |
19
18
2
|
2020 |
Open access
4
4
|
2020 |
Open access
15
12
4
|
2020 |
Open access
6
6
1
|
2020 |
11
10
3
|
2020 |
Open access
12
10
204
|
2020 |
Open access
17
16
9
|
2020 |
Open access
11
11
13
|
2020 |
Open access
36
33
8
|
2020 |
24
23
15
|
2020 |
15
14
6
|
2019 |
Open access
22
21
4
|
2019 |
Open access
47
45
|
2019 |
64
61
2
|
2019 |
Open access
13
13
|
2019 |
9
9
121
|
2019 |
9
7
2
|
2019 |
Open access
59
55
4
|
2019 |
Open access
4
3
4
|
2019 |
27
23
|
2019 |
Open access
7
7
|
2019 |
22
21
|
2019 |
Open access
33
30
19
|
2019 |
Open access
4
3
3
|
2018 |
7
9
2
|
2018 |
15
13
5
|
2018 |
Open access
376
354
132
|
2018 |
4
3
1
|
2018 |
12
12
7
|
2018 |
19
19
|
2018 |
21
21
2
|
2018 |
Open access
17
13
2
|
2018 |
Open access
11
11
1
|
2018 |
Open access
7
9
6
|
2018 |
35
34
4
|
2018 |
Open access
14
12
1
|
2018 |
11
9
13
|
2018 |
13
12
4
|
2017 |
Open access
8
7
|
2017 |
Open access
23
22
12
|
2017 |
25
23
|
2017 |
Open access
22
21
|
2017 |
9
7
1
|
2017 |
Open access
10
9
|
2017 |
19
18
6
|
2017 |
|
2017 |
63
61
|
2017 |
37
36
3
|
2017 |
Open access
50
45
11
|
2017 |
Open access
38
30
19
|
2017 |
21
19
|
2016 |
20
19
4
|
2016 |
36
35
|
2016 |
48
47
16
|
2016 |
Open access
11
10
|
2016 |
Open access
35
34
|
2016 |
Open access
49
43
3
|
2016 |
33
31
4
|
2016 |
30
30
|
2016 |
2
|
2016 |
31
31
|
2016 |
30
28
|
2016 |
25
24
1
|
2016 |
27
28
|
2016 |
3
|
2016 |
7
5
|
2016 |
Open access
71
62
1
|
2016 |
Open access
15
12
34
|
2016 |
37
34
2
|
2016 |
Open access
36
35
2
|
2016 |
8
8
|
2015 |
Open access
12
12
3
|
2015 |
13
14
|
2015 |
Open access
182
174
263
|
2015 |
Open access
55
53
14
|
2015 |
Open access
21
22
1
|
2015 |
22
22
|
2015 |
29
27
4
|
2015 |
27
25
1
|
2015 |
Open access
9
8
3
|
2015 |
26
25
|
2015 |
21
21
|
2014 |
33
30
|
2014 |
Open access
35
31
1
|
2014 |
Open access
46
46
|
2014 |
71
66
3
|
2014 |
Open access
40
35
|
2014 |
32
25
|
2014 |
Open access
21
24
10
|
2014 |
Open access
36
31
|
2014 |
Open access
11
11
|
2014 |
17
15
|
2014 |
24
21
3
|
2013 |
153
150
14
|
2013 |
26
18
|
2013 |
28
30
|
2013 |
9
10
|
2013 |
Open access
6
4
|
2013 |
45
41
5
|
2013 |
34
31
|
2013 |
Open access
4
3
|
2013 |
Open access
5
|
2013 |
50
49
|
2013 |
120
109
9
|
2013 |
Open access
|
2012 |
81
72
2
|
2012 |
33
31
|
2012 |
25
24
|
2012 |
86
76
|
2012 |
41
38
|
2012 |
Open access
17
16
|
2012 |
47
40
19
|
2012 |
Open access
21
21
9
|
2011 |
44
43
|
2011 |
40
37
|
2011 |
49
42
|
2011 |
28
25
|
2011 |
34
32
|
2011 |
31
30
|
2011 |
45
40
|
2011 |
37
|
2011 |
47
46
|
2010 |
40
37
|
2010 |
Open access
25
20
|
2010 |
31
31
|
2010 |
17
15
|
2010 |
45
44
|
2010 |
22
19
|
2010 |
82
62
|
2010 |
85
77
|
2010 |
122
108
|
2010 |
124
108
|
2009 |
28
26
|
2009 |
75
66
|
2009 |
70
60
|
2009 |
31
26
|
2009 |
18
|
2009 |
97
87
|
2009 |
158
143
|
2008 |
5
6
|
2008 |
5
5
|
2008 |
33
32
|
2008 |
46
44
|
2008 |
34
29
|
2008 |
53
52
|
2008 |
41
38
|
2008 |
20
17
|
2008 |
Open access
7
7
|
2008 |
30
27
|
Research
The Prestidge research group is focused on Nanomedicine and BioPharmaceutical Engineering. Its Primary Mission is to: (1) Engineer novel particle based biomaterials with specific biological activity and their application to solve biopharmaceutical challenges. (2) Determine mechanisms for bioactivity through advanced biophysical analysis (3) Develop drug delivery solutions to address unmet clinical needs. Some of our Grand Challenges are to: (1) Deliver Challenging Therapeutic Molecules – For Better Medicines (2) Eradicate Bacterial Biofilms (3) Optimise Biotech and Pharmaceutical Processing and Manufacture
Research
Details | Registry | Status |
---|---|---|
Dried formulations of nanoparticle-coated capsules Prestidge, Clive Allan; Simovic, Spomenka |
AU | Granted |
Dried formulations of nanoparticle-coated capsules Prestidge, Clive Allan; Simovic, Spomenka |
JP | Granted |
Dried formulations of nanoparticle-coated capsules Prestidge, Clive Allan; Simovic, Spomenka |
US | Granted |
Drug delivery composition comprising polymer-lipid hybrid microparticles Prestidge, Clive Allan; Joyce, Paul Matthew |
Australia | Filed |
Drug release from nanoparticle-coated capsules Prestidge, Clive Allan; Simovic, Spomenk; Ghouchi Eskandar, Nasrin |
AU | Granted |
Drug release from nanoparticle-coated capsules Prestidge, Clive; Simovic, Spomenk; Ghouchi, Eskandar Nasrin |
EP | Filed |
Drug release from nanoparticle-coated capsules Prestidge, Clive; Simovic, Spomenk; Ghouchi, Eskandar Nasrin |
US | Granted |
Drug release from nanoparticle-coated capsules Prestidge, Clive; Simovic, Spomenk; Ghouchi Eskandar, Nasrin |
WO | Filed |
Nanoparticle-stabilized capsule formulation for treatment of inflammation Prestidge, Clive; Simovic, Spomenk |
US | Granted |
External engagement & recognition
Organisation | Country |
---|---|
Academia Sinica | TAIWAN |
Adelaide Pathology Partners | AUSTRALIA |
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology | AUSTRALIA |
Australian Centre for Applied Aquaculture Research | AUSTRALIA |
Australian Nuclear Science and Technology Organisation | AUSTRALIA |
Australian Research Council (ARC) | AUSTRALIA |
Australian Synchrotron | AUSTRALIA |
Behala College | INDIA |
Central Adelaide Local Health Network Incorporated | AUSTRALIA |
Ceramisphere | AUSTRALIA |
CeramiSphere Pty Ltd | AUSTRALIA |
Chalmers University of Technology | SWEDEN |
Children's Cancer Institute Australia | AUSTRALIA |
Clinpath Laboratories | AUSTRALIA |
CSIRO Australia (Commonwealth Scientific Industrial Research Organisation) | AUSTRALIA |
Daping Hospital | CHINA |
Department of Surgery | UNITED STATES |
Eurofins Panlabs | BELGIUM |
Fermiscan Holdings Ltd. | AUSTRALIA |
First Affiliated Hospital of Zhengzhou University | CHINA |
Flinders University | AUSTRALIA |
Georgia Institute of Technology | UNITED STATES |
Ghent University | BELGIUM |
Glantreo Limited | IRELAND |
Hanson Institute | AUSTRALIA |
Harbin Institute of Technology | CHINA |
Helmholtz Institute for Pharmaceutical Research Saarland | GERMANY |
Hong Kong Institute of Education | HONG KONG |
Hudson Institute of Medical Research | AUSTRALIA |
Imperial College of Science, Technology and Medicine | UNITED KINGDOM |
Institut Charles Gerhardt Montpellier | FRANCE |
Jadavpur University | INDIA |
Johnson & Johnson | UNITED STATES |
Macquarie University | AUSTRALIA |
Massey University | NEW ZEALAND |
Max Planck Institute for Molecular Genetics | GERMANY |
McGill University | CANADA |
Memorial Sloan Kettering Cancer Centre | UNITED STATES |
Micromyx | UNITED STATES |
Monash University | AUSTRALIA |
Murdoch University | AUSTRALIA |
Naresuan University | THAILAND |
Ohio State University | UNITED STATES |
Oulu University | FINLAND |
Oulun Yliopisto | FINLAND |
pSiMedica Ltd | UNITED KINGDOM |
pSivida Limited | AUSTRALIA |
Queen Elizabeth Hospital | AUSTRALIA |
RDC Clinical Pty Ltd | AUSTRALIA |
Royal Adelaide Hospital | AUSTRALIA |
Rush University | UNITED STATES |
South Australian Health and Medical Research Institute (SAHMRI) | AUSTRALIA |
Starpharma | AUSTRALIA |
Sung Kyun Kwan University | KOREA, REPUBLIC OF (SOUTH) |
Swiss Federal Institute of Technology Zurich (ETH) | SWITZERLAND |
The Hospital for Sick Children | CANADA |
The University of Wollongong | AUSTRALIA |
Tianjin Hospital | CHINA |
Umeå University | SWEDEN |
University College Dublin | IRELAND |
University of Adelaide | AUSTRALIA |
University of Bristol | UNITED KINGDOM |
University of California | UNITED STATES |
University of Copenhagen | DENMARK |
University of Ferrara | ITALY |
University of Hamburg | GERMANY |
University of Ljubljana | SLOVENIA |
University of Melbourne | AUSTRALIA |
University of New South Wales | AUSTRALIA |
University of North Bengal | INDIA |
University of Nottingham | UNITED KINGDOM |
University of Otago | NEW ZEALAND |
University of Queensland | AUSTRALIA |
University of South Australia | AUSTRALIA |
University of Sydney | AUSTRALIA |
University of Technology Sydney | AUSTRALIA |
University of Tokyo | JAPAN |
University of Toronto | CANADA |
University of Warwick | UNITED KINGDOM |
University of Western Australia | AUSTRALIA |
University of Wisconsin-Madison | UNITED STATES |
Uppsala Biomedicinska Centrum | SWEDEN |
Uppsala University | SWEDEN |
Victoria University | AUSTRALIA |
Women's and Children's Hospital | AUSTRALIA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
MemberRoyal Australian Chemical Institute (RACI) |
2017 |
MemberControlled Release Society |
2017 |
MemberAmerican Association of Pharmaceutical Science (AAPS) |
2017 |
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
110496 - Lipid-based Nanocarrier Enabled Delivery for Improved T-cell Immunotherapy | Current |
110502 - Developing advanced oral delivery formulations for treating leukemia | Current |
111602 - Improving mental health therapies by targeting the gut microbiome | Current |
Biomimetic lipid prodrugs: balancing gastrointestinal toxicities and efficacy in oral chemotherapy | Current |
Conquering antimicrobial resistant Gram-negative bacteria to address unmet clinical needs | Current |
Design of Lipid Nanoparticles (LNPs) for mRNA-Based Cancer Vaccines | Current |
Developing advanced oral delivery systems for antiviral drugs | Current |
Development of a safe biomaterial-based therapy for obesity | Current |
Exploring the impact of formulation design on PUFA pharmacokinetics and biodistribution | Current |
Lipid liquid crystalline nanoparticles: a delivery system for antimicrobial photodynamic therapy | Current |
Lipid nanoparticles for delivery of nucleic acid vaccines | Current |
Lipid-based formulations to overcome challenges in oral drugdelivery | Current |
Molecular mechanisms of M cell signalling in the small intestine | Current |
Overcoming biological barriers in treating intracellular infections using lipid-based nanoparticles | Current |
The role of brain derived neurotrophic factor and the neurotrophin receptor p75NTR in the pathogenesis of Alzheimer¿s disease | Current |
Understanding the Biological Performance of Plant Derived Fats and Proteins - Towards Improved Meat Analogues | Current |
A combined lipophilic prodrug and lipid-based drug delivery approach to enable oral chemotherapy (with SN38) | Completed |
Beyond the gastrointestinal cell layer: replication of the complex oral absorption barrier through enhanced in vitro models for nanoparticulate oral protein delivery | Completed |
Cationic polymer mediated siRNA complexes: relationship between intracellular delivery and physicochemical properties | Completed |
Combining porous nanostructure and lipid carriers to improve oral delivery systems for poorly water soluble drugs | Completed |
Dendrimers interactions with lipid bilayers: mechanistic and kinetic studies | Completed |
Designing nanostructured biomaterials with specific activities towards digestive enzymes for controlled lipid hydrolysis | Completed |
Development of imaging methods/models to study oral vaccination and/or delivery of biologics | Completed |
Improving nitric oxide delivery to staphylococcus aureus biofilms | Completed |
Lipid liquid crystal nanostructures to enhance the delivery and efficacy of antimicrobials against bacterial biofilms | Completed |
Lipoceramic microparticles for enhancing oral anticancer drug delivery | Completed |
Liposome-micelle hybrid systems for oral delivery of poorly water-soluble cardiovascular drug lovastatin and anticancer drugs paclitaxel and 5-fluorouracil | Completed |
Microfluidic intestine-on-a-chip in vitro models for improved mechanistic understanding of intestinal drug and particulate carrier uptake | Completed |
Microfluidic intestine-on-a-chip in vitro models for improved understanding of intestinal particulate carrier absorption and interaction with mucus | Completed |
Multi-compartmental emulsion systems for the oral delivery of subunit vaccines | Completed |
Nanoparticle coated liposomes for encapsulation and delivery of proteins | Completed |
Nanostructured clay materials for solidifying lipid-based drug delivery systems | Completed |
Novel glyceryl monooleate (GMO) cubosomes stabilized using silica nanoparticles for the oral delivery of poorly water soluble drugs | Completed |
Optimising the interfacial properties of porous silicon for effective control of molecular and biomolecular interactions | Completed |
Optimizing silica encapsulated lipid-based oral drug delivery systems | Completed |
Physicochemical and biopharmaceutical investigations of novel drug delivery systems for oral administration of poorly water-soluble drugs: Silica-lipid hybrid microcapsules | Completed |
Polymeric micelles to improve the delivery of poorly soluble antimicrobial agents to bacterial and fungal biofilms | Completed |
Polymer-lipid hybrid microparticles enhance the intracellular uptake and activity of rifampicin against bacterially infected macrophages | Completed |
Porous silicon as a delivery system for poorly soluble drugs | Completed |
Solid nanostructured formulations for the oral delivery of poorly water-soluble drugs: from bench to bedside | Completed |
Supersaturated silica-lipid hybrids - overcoming the challenges of oral drug delivery | Completed |
The impact of formulating 5-Fluorouracil into liposomes on its site-specific delivery to tumour tissue | Completed |